8-K: BIO-key Q1 Results Show 34% Revenue Jump, Profitability Expected

BIO-key International reports a 34% revenue increase in Q1 2026, with significant improvements in net loss, and anticipates profitability in Q2 2026 driven by a projected 65% revenue surge.

Summary

• BIO-key International announced its first quarter 2026 financial results, reporting a 34% increase in revenue to $2.15 million compared to the same period in 2025.
• The company's net loss significantly improved, narrowing to $165,000 in Q1 2026 from $737,000 in Q1 2025 and $1.722 million in Q4 2025.
• BIO-key ended the first quarter with $2.24 million in cash and cash equivalents.
• For the second quarter of 2026, the company projects revenue to grow by 65% to approximately $2.8 million.
• The outlook for the first half of 2026 anticipates revenue growth of 50% to $5 million and a return to profitability, contrasting with a $1.9 million net loss in the first half of 2025.
• Significant sector progress was noted, including a $1.04 million biometric identity license renewal in finance, over $2 million in military/defense sales in the last twelve months, and new partnerships in the U.S. public sector.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive filing, with strong revenue growth, significant improvement in net loss, and a confident outlook for profitability and continued growth, despite the Nasdaq suspension.

Positives

• Revenue increased by 34% to $2.15 million in Q1 2026 compared to Q1 2025.
• Net loss improved to $165,000 in Q1 2026, a substantial reduction from $737,000 in Q1 2025 and $1.722 million in Q4 2025.
• Projected Q2 2026 revenue growth of 65% to approximately $2.8 million.
• Expected profitability in the first half of 2026, compared to a net loss of $1.9 million in the first half of 2025.
• Secured a $1.04 million one-year biometric identity license renewal with a foreign bank.
• Military/Defense sales surpassed $2 million over the latest twelve months.
• Partnership with TD Synnex Public Sector to deliver IAM solutions to the U.S. Public Sector.
• Strong blended gross margin of 82.5%.

Negatives

• The company reported a net loss of $165,000 in Q1 2026, despite the improvement.
• Stock shares were recently suspended from Nasdaq, though efforts are underway to relist.
• The review of Q1 2026 financial statements has not been completed by the independent registered public accounting firm and is subject to change.

Risks

• The company's history of losses and limited revenue.
• The ability to raise additional capital to satisfy working capital needs.
• The ability to continue as a going concern.
• The ability to protect intellectual property.
• Changes in business conditions, sales strategy, product development plans, and the marketplace.
• Competition in the biometric technology and identity access management industries.
• Market acceptance of biometric products.
• Potential for security breaches.

Future Outlook

BIO-key expects Q2 2026 revenues to increase by 65% to approximately $2.8 million, and anticipates achieving profitability in the first half of 2026, with revenues projected to rise 50% to $5 million compared to the first half of 2025. The company expects its cash position to remain in line with current levels and forecasts solid revenue growth and improved bottom-line performance for the full year 2026.

Management Comments

• "Our Q126 results reflect the benefit of our sales, marketing and customer development initiatives over the past several quarters, combined with globally expanding appreciation for the unparalleled value that biometric identity and access management solutions provide in securing mission critical applications and data."
• "In addition to solid revenue growth - both from new and existing customers - we substantially improved our bottom-line performance reflecting a blended gross margin of 82.5% and our ongoing cost management discipline."
• "We continue to see strength with foreign government, defense and financial customers that increasingly recognize the mission critical security and value of our suite of biometrically enhanced authentication solutions."
• "Our business is off to a strong start in 2026, and we are excited about our outlook for Q2 and the remainder of the year. We believe BIO-key has never been better positioned for growth and improved financial performance."

Industry Context

StockSavvy.ai notes that BIO-key's performance aligns with the growing global demand for robust identity and access management (IAM) and biometric authentication solutions, driven by increasing cybersecurity threats and regulatory mandates across finance, defense, and government sectors. The company's strategic partnerships and contract wins in these critical areas reflect broader industry trends towards enhanced digital security.

Comparison to Industry Standards

• No direct comparisons to specific global benchmarks or named competitors were provided in the filing.
• The company highlights its own growth metrics (e.g., 34% Q1 revenue increase) and sector-specific wins (e.g., $1.04M license renewal, $2M+ defense sales) as indicators of its market position.

Legal Proceedings

• The company is actively working to return its shares to the Nasdaq Capital Market after their recent suspension, though timing and success are uncertain.

Stakeholder Impact

• Shareholders: Potential for improved financial performance and stock value if Nasdaq relisting is successful and growth targets are met. Current uncertainty due to Nasdaq suspension.
• Employees: Continued employment and potential growth opportunities with company expansion.
• Customers: Continued access to and development of identity and access management solutions.
• Partners: Opportunities for collaboration and revenue generation through partnerships like TD Synnex Public Sector.

Next Steps

• Host investor call on May 18th at 10:00 AM ET.
• Continue efforts to return shares to the Nasdaq Capital Market.
• Execute on Q2 and full-year 2026 growth and profitability expectations.

Key Dates

Recommendation

The company shows strong operational improvements and a positive outlook, but the recent suspension from Nasdaq introduces significant uncertainty. While the Q1 results and future projections are encouraging, the path back to Nasdaq and sustained profitability requires further validation. Investors should hold to monitor these developments.

Keywords

BIO-key International, Identity and Access Management, Biometric Authentication, Q1 2026 Results, Revenue Growth, Financial Outlook, Cybersecurity, IAM Solutions